Gadoterate meglumine

(Dotarem®)

Gadoterate meglumine

Latest News

loading GIF

Drug updated on 4/24/2024

Dosage FormInjection (intravenous; 0.5 mmol/mL containing 376.9 mg/mL gadoterate meglumine)
Drug ClassGadolinium-based contrast imaging agents
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (including term neonates) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Gadoterate meglumine (Dotarem) is indicated for intravenous use with magnetic resonance imaging in brain, spine, and associated tissues to detect and visualize areas with disruption of the blood-brain barrier or abnormal vascularity.
  • Two systematic reviews/meta-analyses provided information on the safety and effectiveness of Gadoterate meglumine compared to other gadolinium-based contrast agents.
  • The first study highlighted that symptoms associated with gadolinium exposure represent a notable percentage of adverse events reported. However, it was found that Gadoterate meglumine exhibited a substantially lower percentage of these symptoms compared to other drugs like gadobenate dimeglumine and gadoteridol, suggesting a better safety profile.
  • The second study focused on the risk assessment among patients with stage 4 or 5 chronic kidney disease who received group II gadolinium-based contrast agents, including Gadoterate meglumine. It revealed negligible incidence rates for Nephrogenic Systemic Fibrosis (NSF), indicating a favorable safety profile, especially in patients with compromised renal function.
  • In terms of population types and subgroup considerations, Gadoterate meglumine seems safer for general populations, including both adult and pediatric patients, due to its fewer associated symptoms and those suffering from chronic kidney disease due to a low NSF risk factor according to the analysis presented.
  • The overall comparison suggests that while all Group II gadolinium-based contrast agents have similar profiles, Gadoterate meglumine stands out because it has been shown through studies that this drug presents fewer risks specifically towards the occurrence of severe adverse events alongside almost no cases leading towards NSF making it an ideal choice amongst high-risk patient groups such as those diagnosed with chronic kidney disease.